Mannkind (MNKD) News and press releases

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 24, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD), a company focused on the development and commercialization of innovative therapeutic products for patients

https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/214324s000lbl.pdf

https://www.stockilluminati.com/mnkd/display.php?url=https%3a%2f%2fseekingalpha.com%2fnews%2f3841862-uthr-stock-mnkd-stock-gain-as-fda-approve-lung-disease-therapy%3futm_source%3dfeed_news_all%26utm_medium%3dreferral

Here's a roundup of top developments in the biotech space over the last 24 hours:

Deal includes $10 million USD upfront payment to Zealand and sales-based milestones Certain inventory related to V-Go® and employees also included under the terms of the deal Agreement is part of Zealand’s

MannKind (NASDAQ:MNKD) reported quarterly losses of $(0.10) per share which met the analyst consensus estimate. This is a 100 percent decrease over losses of $(0.05) per share from the same period last year. The company

Companies Reporting Before The Bell • Mirum Pharmaceuticals (NASDAQ:MIRM) is expected to report quarterly loss at $1.34 per share on revenue of $8.46 million.

MannKind (NASDAQ:MNKD) is set to give its latest quarterly earnings report on Thursday, 2022-05-05. Here's what investors need to know before the announcement. Analysts estimate that MannKind will report an earnings per share (EPS) of $-0.10.

MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced today that it has presented a poster [Abstract #445] at the 15th International Conference on Advanced Technologies & Treatments for Dia

WESTLAKE VILLAGE, Calif., June 03, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD), a company focused on the development and commercialization of innovative therapeutic products for patients with endocrine

Tyvaso DPI represents the second FDA-approved product utilizing MannKind's Technosphere® inhalation technologyFirst approval of a dry powder inhaled treatment for PAH and PH-ILDManufacturing of Tyvaso DPI for United

WESTLAKE VILLAGE, Calif. and DANBURY, Conn., May 19, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients

The once-daily insulin delivery device strengthens MannKind's commitment to offering innovative mealtime diabetes solutions DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 17, 2022 (GLOBE NEWSWIRE) -- MannKind

Company announcement – No. 21 / 2022 Zealand Pharma Announces Asset Purchase Agreement with MannKind Corporation for V-Go® Insulin Delivery Device Deal includes $10 million USD upfront payment to Zealand and

WESTLAKE VILLAGE, Calif. and DANBURY, Conn., May 09, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients

1Q 2022 Afrezza Net Revenue of $9.8 million; +21% vs. 1Q 20211Q 2022 Afrezza Gross Margin 77%; Gross Profit +99% vs 1Q 2021$233.0 million of Cash, Cash Equivalents, and Investments at March 31, 2022Tyvaso DPI PDUFA date

Simplified 2x dose of Technosphere® Insulin (TI) produced a statistically significant improvement in PPGE between Dose 1 & 2 from 45-120 minutesHigher dose of TI resulted in a mean difference of 52 mg/dL in PPGE